Publicaciones en colaboración con investigadores/as de University of Vienna (16)

2023

  1. COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes. A multicontinental cohort study

    Journal of Medical Virology, Vol. 95, Núm. 5

  2. Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study

    eLife, Vol. 12

2022

  1. Development and evaluation of a machine learning-based in-hospital COVID-19 disease outcome predictor (CODOP): A multicontinental retrospective study

    eLife, Vol. 11

  2. Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 1

2021

  1. Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 6, pp. 1498-1510

2018

  1. Interplay between gut microbiota metabolism and inflammation in HIV infection

    ISME Journal, Vol. 12, Núm. 8, pp. 1964-1976

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. Relationship between arterial access and outcomes in ST-elevation myocardial infarction with a pharmacoinvasive versus primary percutaneous coronary intervention strategy: Insights from the STrategic reperfusion early after myocardial infarction (STREAM) study

    Journal of the American Heart Association, Vol. 5, Núm. 6

2014

  1. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1269-1278

2011

  1. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers

    Human Genetics, Vol. 130, Núm. 5, pp. 685-699

  2. Symptomatic therapy in multiple sclerosis: A review for a multimodal approach in clinical practice

    Therapeutic Advances in Neurological Disorders, Vol. 4, Núm. 3, pp. 139-168

2010

  1. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database

    Journal of Rheumatology, Vol. 37, Núm. 7, pp. 1488-1501

  2. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

    Nature Genetics, Vol. 42, Núm. 5, pp. 426-429

  3. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177

2005

  1. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583